|
GB0526211D0
(en)
*
|
2005-12-22 |
2006-02-01 |
Oxford Biomedica Ltd |
Viral vectors
|
|
WO2007091066A1
(en)
*
|
2006-02-07 |
2007-08-16 |
Ucl Business Plc |
Applications of non-integrating lentiviral vectors
|
|
AU2013203416B2
(en)
*
|
2007-08-03 |
2016-10-13 |
Centre National De La Recherche Scientifique (Cnrs) |
Lentiviral gene transfer vectors and their medicinal applications
|
|
EP2020444B1
(en)
*
|
2007-08-03 |
2017-05-31 |
Institut Pasteur |
Defective non-integrative lentiviral transfer vectors for vaccines
|
|
CA2695433C
(en)
|
2007-08-03 |
2025-05-06 |
Institut Pasteur |
Antiviral gene transfer vectors and their medicinal applications
|
|
AU2008317354B2
(en)
|
2007-10-25 |
2014-04-10 |
Ospedale San Raffaele S.R.L. |
Methods and compositions for targeted integration
|
|
JP2011517409A
(ja)
*
|
2008-03-28 |
2011-06-09 |
バイレクシス コーポレイション |
レンチウイルスベースの免疫原性ベクター
|
|
WO2009131706A1
(en)
*
|
2008-04-26 |
2009-10-29 |
Yung-Nien Chang |
Site-specific-integration lentiviral vectors
|
|
WO2010105251A2
(en)
*
|
2009-03-13 |
2010-09-16 |
Lentigen Corporation |
Non-integrating retroviral vector vaccines
|
|
CA2756833C
(en)
|
2009-04-09 |
2019-11-19 |
Sangamo Therapeutics, Inc. |
Targeted integration into stem cells
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
JP2013518602A
(ja)
|
2010-02-09 |
2013-05-23 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
部分的に一本鎖のドナー分子による標的化ゲノム改変
|
|
EP2385107B1
(en)
|
2010-05-03 |
2016-08-24 |
Institut Pasteur |
Lentiviral vector based immunological compounds against malaria
|
|
WO2012152912A1
(en)
|
2011-05-12 |
2012-11-15 |
Newvectys |
Genetically modified pig as a cancer prone model
|
|
ES2651922T3
(es)
|
2011-11-08 |
2018-01-30 |
Institut Pasteur |
Polipéptidos de afinidad elevada para MAST2 y usos de los mismos
|
|
GB201202516D0
(en)
|
2012-02-13 |
2012-03-28 |
Ucl Business Plc |
Materials and methods relating to packaging cell lines
|
|
DK2831095T3
(en)
|
2012-03-30 |
2019-02-18 |
Immune Design Corp |
LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN
|
|
US9713635B2
(en)
|
2012-03-30 |
2017-07-25 |
Immune Design Corp. |
Materials and methods for producing improved lentiviral vector particles
|
|
WO2014093701A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
IL239317B
(en)
|
2012-12-12 |
2022-07-01 |
Broad Inst Inc |
Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
EP3434776A1
(en)
|
2012-12-12 |
2019-01-30 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
CA2907397C
(en)
|
2013-03-15 |
2022-11-22 |
Anthrogenesis Corporation |
Modified t lymphocytes
|
|
CN105793425B
(zh)
*
|
2013-06-17 |
2021-10-26 |
布罗德研究所有限公司 |
使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
JP6738729B2
(ja)
*
|
2013-06-17 |
2020-08-12 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
分裂終了細胞の疾患および障害をターゲティングおよびモデリングするための系、方法および組成物の送達、エンジニアリングおよび最適化
|
|
MX2015017312A
(es)
|
2013-06-17 |
2017-04-10 |
Broad Inst Inc |
Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas.
|
|
EP3725885A1
(en)
|
2013-06-17 |
2020-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
WO2014204724A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
|
JP6665088B2
(ja)
|
2013-06-17 |
2020-03-13 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
配列操作のための最適化されたＣＲＩＳＰＲ−Ｃａｓ二重ニッカーゼ系、方法および組成物
|
|
EP3046930A1
(en)
*
|
2013-09-17 |
2016-07-27 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Lentiviral vectors having a mutated integrase protein and uses thereof
|
|
EP2878667A1
(en)
|
2013-11-29 |
2015-06-03 |
Institut Pasteur |
TAL effector means useful for partial or full deletion of DNA tandem repeats
|
|
WO2015089473A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
CN111206032B
(zh)
|
2013-12-12 |
2024-07-19 |
布罗德研究所有限公司 |
用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
|
RU2016128077A
(ru)
|
2013-12-12 |
2018-12-06 |
Те Брод Инститьют Инк. |
Доставка, применение и применения в терапии систем и композиций crispr-cas для лечения обусловленных hbv и вирусных заболеваний и нарушений
|
|
BR112016013547A2
(pt)
|
2013-12-12 |
2017-10-03 |
Broad Inst Inc |
Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
GB201322798D0
(en)
|
2013-12-20 |
2014-02-05 |
Oxford Biomedica Ltd |
Production system
|
|
EP3738597A1
(en)
|
2014-04-25 |
2020-11-18 |
Bluebird Bio, Inc. |
Improved methods for manufacturing adoptive cell therapies
|
|
IL296691B2
(en)
|
2014-04-25 |
2023-11-01 |
2Seventy Bio Inc |
MND promoter chimeric antigen receptors
|
|
CN106793780B
(zh)
|
2014-06-06 |
2020-05-26 |
蓝鸟生物公司 |
改善的t细胞组合物
|
|
MX2017001079A
(es)
|
2014-07-24 |
2017-09-12 |
Bluebird Bio Inc |
Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
|
|
EP3031923A1
(en)
*
|
2014-12-11 |
2016-06-15 |
Institut Pasteur |
Lentiviral vector-based japanese encephalitis immunogenic composition
|
|
EP3230451B1
(en)
|
2014-12-12 |
2021-04-07 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
EP3971210A1
(en)
|
2014-12-12 |
2022-03-23 |
2seventy bio, Inc. |
Composition for use in the treatment of b cell related conditions in a subject in need thereof comprisine an effector cell comrising a bcma chimeric antigen receptors
|
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
|
IL293323B2
(en)
|
2015-06-18 |
2024-01-01 |
Massachusetts Inst Technology |
Crispr enzyme mutations reducing off-target effects
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
WO2017053707A1
(en)
|
2015-09-23 |
2017-03-30 |
Sensoriant, Inc. |
Method and system for using device states and user preferences to create user-friendly environments
|
|
WO2017060662A1
(en)
*
|
2015-10-07 |
2017-04-13 |
The Secretary Of State For Health |
Method for providing a control for use in a screen for pathogenic virus
|
|
WO2017099712A1
(en)
|
2015-12-07 |
2017-06-15 |
Bluebird Bio, Inc. |
Improved t cell compositions
|
|
WO2017180993A1
(en)
|
2016-04-14 |
2017-10-19 |
Bluebird Bio, Inc. |
Salvage chimeric antigen receptor systems
|
|
WO2017214938A1
(zh)
*
|
2016-06-16 |
2017-12-21 |
毛侃琅 |
特异促进 bace1 基因高表达的慢病毒表达载体及应用
|
|
WO2018035141A1
(en)
|
2016-08-16 |
2018-02-22 |
Bluebird Bio, Inc. |
Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use
|
|
CA3034782A1
(en)
|
2016-08-23 |
2018-03-01 |
Bluebird Bio, Inc. |
Tim3 homing endonuclease variants, compositions, and methods of use
|
|
BR112019004629A2
(pt)
|
2016-09-08 |
2019-10-01 |
Bluebird Bio, Inc. |
variantes de endonuclease de homing pd-1, composições e métodos de uso
|
|
MA46543A
(fr)
|
2016-10-17 |
2019-08-21 |
Bluebird Bio Inc |
Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation
|
|
KR20240005168A
(ko)
|
2016-11-04 |
2024-01-11 |
2세븐티 바이오, 인코포레이티드 |
항-bcma car t 세포 조성물
|
|
DK3541833T5
(da)
|
2016-11-17 |
2024-09-02 |
2Seventy Bio Inc |
TGFß signalkonverter
|
|
RU2019120721A
(ru)
*
|
2016-12-06 |
2021-01-11 |
Блубёрд Био, Инк. |
Генная терапия для лечения мукополисахаридоза i типа
|
|
AU2017370673A1
(en)
*
|
2016-12-06 |
2019-06-27 |
Bluebird Bio, Inc. |
Gene therapy for mucopolysaccharidosis, type II
|
|
EP3357504A1
(en)
|
2017-02-02 |
2018-08-08 |
Institut Pasteur |
Functional screening of antigenic polypeptides - use for the identification of antigens eliciting a protective immune response and for the selection of antigens with optimal protective activity
|
|
EP3357506A1
(en)
|
2017-02-02 |
2018-08-08 |
Institut Pasteur |
Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host
|
|
AU2018221730B2
(en)
|
2017-02-15 |
2024-06-20 |
Novo Nordisk A/S |
Donor repair templates multiplex genome editing
|
|
EP3630962A4
(en)
|
2017-05-25 |
2021-01-20 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
|
WO2019070974A1
(en)
|
2017-10-04 |
2019-04-11 |
Bluebird Bio, Inc. |
PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
|
|
EP3696272A1
(en)
|
2017-12-22 |
2020-08-19 |
Oxford BioMedica (UK) Limited |
Retroviral vector
|
|
DE102018100967B4
(de)
|
2018-01-17 |
2019-08-14 |
Immatics US, Inc. |
Verfahren zur feststellung der wirksamkeit von viralen vektoren
|
|
DE102018010282A1
(de)
|
2018-01-17 |
2019-07-18 |
Immatics US, Inc. |
Verfahren zur Feststellung der Wirksamkeit von viralen Vektoren
|
|
DK3806903T5
(da)
|
2018-06-14 |
2024-08-19 |
2Seventy Bio Inc |
Cd79a kimæriske antigenreceptorer
|
|
CN112689516A
(zh)
|
2018-07-11 |
2021-04-20 |
细胞基因公司 |
抗bcma嵌合抗原受体的用途
|
|
WO2020047467A2
(en)
|
2018-08-30 |
2020-03-05 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with myocardin and ascl1
|
|
WO2020072059A1
(en)
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
|
US12404500B2
(en)
|
2018-12-10 |
2025-09-02 |
Novo Nordisk A/S |
Homing endonuclease variants
|
|
AU2019395334B2
(en)
|
2018-12-10 |
2026-04-23 |
Regeneron Pharmaceuticals, Inc. |
PDCD-1 homing endonuclease variants
|
|
EP3895052A4
(en)
|
2018-12-14 |
2022-10-26 |
2seventy bio, Inc. |
DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES
|
|
WO2020205889A1
(en)
|
2019-04-01 |
2020-10-08 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
WO2021007515A1
(en)
|
2019-07-11 |
2021-01-14 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
|
EP3770264A1
(en)
|
2019-07-22 |
2021-01-27 |
Genethon |
Precise integration using nuclease targeted idlv
|
|
WO2021051390A1
(zh)
|
2019-09-20 |
2021-03-25 |
上海吉倍生物技术有限公司 |
靶向bcma的抗体及嵌合抗原受体
|
|
CA3160178A1
(en)
|
2019-11-05 |
2021-05-14 |
Celgene Corporation |
Uses of anti-bcma chimeric antigen receptors
|
|
KR20220097492A
(ko)
|
2019-11-12 |
2022-07-07 |
옥스포드 바이오메디카(유케이) 리미티드 |
생산 시스템
|
|
JP2023513303A
(ja)
|
2020-02-13 |
2023-03-30 |
オックスフォード バイオメディカ（ユーケー）リミテッド |
レンチウイルスベクターの製造
|
|
US20230118587A1
(en)
|
2020-03-13 |
2023-04-20 |
Oxford Biomedica (Uk) Limited |
Lentiviral Vectors
|
|
WO2021212279A1
(zh)
*
|
2020-04-20 |
2021-10-28 |
广东东阳光药业有限公司 |
慢病毒的滴度提高型转移质粒
|
|
CN114807228B
(zh)
*
|
2020-04-27 |
2023-12-15 |
北京化工大学 |
一种t7rna聚合酶和t7启动子的表达系统及使用其在真核生物中表达蛋白质的方法
|
|
GB202007199D0
(en)
|
2020-05-15 |
2020-07-01 |
Oxford Biomedica Ltd |
Viral vector production
|
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
|
JP7415042B2
(ja)
|
2020-10-09 |
2024-01-16 |
テナヤ セラピューティクス， インコーポレイテッド |
プラコフィリン２遺伝子治療の方法および組成物
|
|
EP3984548A1
(en)
|
2020-10-16 |
2022-04-20 |
Institut Pasteur |
Generation of lentiviral vectors enabling routing antigens to mhc-ii pathway and inducing cd4+ and cd8+ t-cell responses immune response in a host
|
|
JP2023550309A
(ja)
|
2020-11-04 |
2023-12-01 |
セルジーン コーポレーション |
以前に抗がんアルキル化剤療法を受けた患者におけるｃａｒ ｔ細胞療法
|
|
GB202017725D0
(en)
|
2020-11-10 |
2020-12-23 |
Oxford Biomedica Ltd |
Method
|
|
EP4272002A1
(en)
|
2020-12-04 |
2023-11-08 |
Celgene Corporation |
Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
|
|
US20250319173A1
(en)
|
2021-03-12 |
2025-10-16 |
Institut Pasteur |
Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host
|
|
AU2022257093A1
(en)
|
2021-04-16 |
2023-11-02 |
Celgene Corporation |
T cell therapy in patients who have had prior stem cell transplant
|
|
AU2022310862A1
(en)
|
2021-07-14 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
|
GB202114530D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Retroviral vectors
|
|
GB202114528D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
GB202114529D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
GB202114534D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Novel viral regulatory elements
|
|
GB202114532D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral Vectors
|
|
CN114181972A
(zh)
*
|
2021-11-23 |
2022-03-15 |
上海本导基因技术有限公司 |
适用于难治性血管新生性眼疾病基因治疗的慢病毒载体
|
|
GB202117844D0
(en)
|
2021-12-09 |
2022-01-26 |
Oxford Biomedica Ltd |
Purification method
|
|
IL316032A
(en)
|
2022-04-08 |
2024-11-01 |
Regeneron Pharma |
Multicomponent receptor and signaling complexes
|
|
CN119365208A
(zh)
|
2022-04-13 |
2025-01-24 |
巴塞罗那自治大学 |
通过表达klotho蛋白的基因疗法治疗神经肌肉疾病
|
|
US20250295771A1
(en)
|
2022-05-11 |
2025-09-25 |
Celgene Corporation |
Methods and uses related to t cell therapy and production of same
|
|
IL317172A
(en)
|
2022-05-26 |
2025-01-01 |
Regeneron Pharma |
Lentiviral vector maintenance vehicles and uses thereof
|
|
GB202211935D0
(en)
|
2022-08-16 |
2022-09-28 |
Oxford Biomedica Ltd |
envelope proteins
|
|
TW202423456A
(zh)
|
2022-10-21 |
2024-06-16 |
法商賽拉福柯蒂斯公司 |
表現選自denv、zikv及yfv之群之黃病毒之非結構抗原、誘導宿主中保護性cd8+t細胞免疫的多核苷酸及慢病毒載體
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
EP4688851A1
(en)
|
2023-03-27 |
2026-02-11 |
LAVA Therapeutics N.V. |
Nectin-4 binding agents and methods of use
|
|
WO2025012118A2
(en)
|
2023-07-07 |
2025-01-16 |
LAVA Therapeutics N.V. |
5t4 binding agents and methods of use
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025153530A1
(en)
|
2024-01-16 |
2025-07-24 |
Novo Nordisk A/S |
Albumin-targeted endonucleases, compositions, and methods of use
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|